Share Name Share Symbol Market Type Share ISIN Share Description
Silence Ther. LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.625p -0.59% 105.75p 105.75p 106.75p 105.75p 105.75p 105.75p 3,687 16:35:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.8 -10.4 -12.1 - 74.02

Silence Therapeutics Share Discussion Threads

Showing 50051 to 50074 of 50075 messages
Chat Pages: 2003  2002  2001  2000  1999  1998  1997  1996  1995  1994  1993  1992  Older
DateSubjectAuthorDiscuss
21/7/2017
12:23
I am the leader of the hordes. Like the look of the chart. Could do another OXB
volsung
20/7/2017
11:09
Just have to wait for the hordes of pharma momentum players to arrive then...
1gw
19/7/2017
21:42
Looks like we have a chart breakout chaps
richie666
11/7/2017
11:20
Thanks for that research find richie - happy to hold patiently as always for the overdue reward (been in this for years!)
callumross
11/7/2017
08:53
How much per share would you accept ?. I would like between £3.50 £4.50 per share , we appear to be game on
partner
11/7/2017
07:53
I like this company a lot but its stock can be illiquid, difficult to trade and volumes are poor I can someone taking out this company simply for its IP portfolio which is where the real value resides
gersemi
11/7/2017
07:44
New Align post - http://www.alignresearch.co.uk/silence-therapeutics/silence-therapeutics-patent-claim-highlights-multi-million-pound-licence-potential/
richie666
10/7/2017
14:35
Paris, France and Cambridge, MA  - July 10, 2017 - Sanofi Genzyme, the specialty care global business unit of Sanofi, and Alnylam Pharmaceuticals, Inc, the leading RNAi therapeutics company, announced today new positive results from the ongoing phase 2 open-label extension (OLE) study with fitusiran in patients with hemophilia A and B, with or without inhibitors (N=33).  These results were presented today in an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress, being held from July 8 - 13, 2017 in Berlin, Germany. Fitusiran is an investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of patients with hemophilia A and B, that is designed to lower levels of AT with the goal of promoting sufficient thrombin generation upon activation of the clotting cascade to restore hemostasis and prevent bleeding. The companies also announced that phase 1 clinical trial results demonstrating an encouraging preliminary safety and tolerability profile and initial evidence that monthly subcutaneously administered fitusiran lowered AT levels and increased thrombin generation in patients with hemophilia A and B without inhibitors were published online today and will appear in the September 7, 2017, print issue of The New England Journal of Medicine (NEJM). The updated clinical results in the fitusiran phase 2 OLE study showed that the safety and tolerability profile of fitusiran remains encouraging, with no thromboembolic events, including during co-administration of replacement factor or bypassing agents. The majority of adverse events (AEs) were mild or moderate in severity, with the most common AEs consisting of transient, mild injection site reactions (ISRs). In addition, once-monthly subcutaneous (SC) administration of fitusiran achieved lowering of AT, increases in thrombin generation, and, in a post-hoc exploratory analysis, reductions in the median estimated annualized bleeding rate (ABR) in patients with and without inhibitors. Based on these results, the companies announced last week the initiation of the ATLAS phase 3 program for fitusiran in patients with hemophilia A and B with or without inhibitors.  "With up to 20 months of dosing in patients, we are encouraged by the results from our fitusiran clinical studies presented at the ISTH meeting today, demonstrating what we believe to be promising support for further clinical development," said Akin Akinc, Ph.D., Alnylam's Vice President and General Manager, Fitusiran. "We're also pleased to have announced initiation of our ATLAS phase 3 program just last week, where the safety and efficacy of fitusiran will be evaluated and where we expect initial results in mid-to-late 2019."
callumross
10/7/2017
07:57
Intriguing to say the least
gersemi
09/7/2017
10:52
https://www.thetimes.co.uk/edition/business/biotech-claims-us-rival-infringed-patent-rrj3v7jnj Could be massive for the stock.
richie666
03/7/2017
15:03
Legal bills going up I see. Hope they're successful with the claim.
1gw
02/6/2017
18:57
What are you quoting from richie666? Did anyone go to the AGM? I gave it a miss this time, so I hope they got their quorum.
1gw
02/6/2017
07:39
Ali has hinted consistently at value of IP.Our own take is that it could be worth north of 60p per share. With cash and ARWR stake we see 150p as a near term tgt
richie666
30/5/2017
09:34
He seems very bullish about the value of this IP. I found this interesting; "Silence is committed to defending and securing the appropriate value for our IP and is exploring alternative ways to leverage this asset." Not actually sure what this means but is it possible they could sell off the IP to a third party to pursue leaving the company free to concentrate on the science?
callumross
30/5/2017
09:30
1gw, I have a long history with SLN and have been out for sometime. Under no illusions but happy to take a small punt at this level.
waterloo01
30/5/2017
09:25
waterloo01 - not for the first time! AM is not shy about his belief in the value of Silence's IP: 30th May "We consider that potential licences under our patent estate could have a significant financial effect relative to the current market capitalisation of Silence" 16th May "We consider that potential licences under our patent estate could have a significant financial effect relative to the current market capitalisation of Silence." 2016 Annual Report (26th April) "As RNAi becomes an established therapeutic approach, the Directors believe that the totality of our IP alone represents a very significant risk/reward upside relative to the market cap and enterprise value of Silence." ... "Not only do we expect to make significant strides in our core business activity of drug development, but we also see material upside in potential licensing and partnering opportunities with companies using our IP." ... "2017/18 will be a critical period in the field of RNAi. As well as announcing our own GalNAc-siRNA pipeline candidates, we await important readouts from competitor clinical studies which will add not only to the viability of RNAi as a new class of therapeutic, but will also potentially have a significant impact upon the value of our IP portfolio." 2015 Annual Report (29th April 2016) "With the commencement of the Quark trials, the approach from a potential licensee and the significant broadening of the AtuRNAi® patent estate, we are of the belief that these opportunities alone could be very significant relative to the current size of the Company."
1gw
30/5/2017
08:42
Interesting RNS. Bought a few to trade on the back of it. Guess they will need to put more into the legals accounts line but 'significant' sums alluded to.
waterloo01
17/5/2017
15:17
Since I've ended up slightly ahead on SLN thanks to the recent price rise, I've taken a bit off the table and re-invested in Arrowhead (SLN's US investment), hoping that averaging down there works as well as it did here.
1gw
17/5/2017
12:39
There is a looong way to go here chaps IMO. 120/130 is starters.
richie666
17/5/2017
09:56
Just on the basis of all the "AT" trades going through, it looks a bit like a determined buyer this morning.
1gw
17/5/2017
09:51
I tried 2k without success, just to try to see what the real price was... Edit - although at 09:54 I can get a firm price on 5k.
1gw
17/5/2017
09:45
There's no seller now as I can't even buy 10k shares ffs. They won't even give me 5k shares
gersemi
17/5/2017
09:38
Thanks for posting the note Richie. Good volume today and by far the best I have seen in the few months that I have been following this stock.
andinvestor1
17/5/2017
09:16
SILENCE THERAPEUTICS – EXPANSION OF INTELLECTUAL PROPERTY PORTFOLIO SUPPORTS FURTHER LONG-TERM VALUE May 16, 2017 | Posted by admin By Richard Gill, CFA The AIM listed RNA therapeutics specialist Silence Therapeutics (SLN) has announced a significant expansion of its chemical modification patent estate. In March this year the company revealed that the European Patent Office had granted a patent covering key RNAi chemical modifications, thus giving it further protection for its technology across many European countries. The company believes that this technology is relevant to third party medicines in ongoing clinical trials for conditions including, but not exclusively limited to, Hypercholesterolemia, TTR-mediated Amyloidosis, Haemophilia and Acute Hepatic Porphyrias. Silence has now further expanded its patent estate by filing additional divisional and continuation patent applications in Europe and the US which it believes are also relevant to the third-party medicines above. The patent filings are in line with the company’s core strategy of growing its intellectual property portfolio, with a view to potential licencing opportunities with third parties. We note comments from CEO Ali Mortazavi that, “we believe that several third party late-stage clinical RNAi candidates, including lipid nanoparticle and GalNAc based products, require licences under our patent portfolio”, thus providing further revenue generating opportunities for the company – Silence already has licence agreements for its IP with partners including Quark Pharmaceuticals and Novartis. Chemical modification technology, such as that developed by Silence, is vital to prevent the degradation of therapeutic short interfering RNA (siRNA) molecules and to improve the impact on the performance of RNA interference (RNAi) based drugs. Shares remain undervalued despite recent recovery On the back of the news Silence Therapeutics shares have advanced by 4.4% as we write to 89.75p. They have recovered from recent lows of 72.875p seen in early May, with the company now capitalised at £62.82 million. The last reported net cash figure (as at 31st December 2016) was £39 million, which rises to £43.4 million if we add in the value of Silence’s stake in US listed Arrowhead Pharmaceuticals (ARWR.NASDAQ) – Arrowhead shares currently trade at a similar price as at 31st December when they were marked to market. Thus, the markets are valuing the Silence Therapeutics business, which incorporates the valuable intellectual property portfolio and programme of clinical trials, at just £19.42 million – read our full initiation blog here for more details. We re-iterate the potential for corporate activity in the sector, believing that Silence Therapeutics’ current valuation is likely to put the company on the radar of a number of potential suitors, whether they be in the RNAi field already or looking to enter the sector by buying a valuable portfolio of RNAi technology. The current enterprise value should prove to be no problem for larger pharma industry players to pay, for example market leader Alnylam Pharmaceuticals (ALNY.NASDAQ) had cash & marketable securities of $740 million as at 31st March 2017. We believe that as newsflow emerges over the next 12 months there could be a return of multiples of the present price and a very real possibility of being acquired, with downside cushioned by the cash pile. We retain a Conviction Buy stance.
richie666
Chat Pages: 2003  2002  2001  2000  1999  1998  1997  1996  1995  1994  1993  1992  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170721 18:54:49